Currently Viewing:
COA Community Oncology Conference 2019
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Strategies for Fighting Consolidation in Community Oncology
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Currently Reading
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy

Real-world data offers a glimpse into what happens to patients treated by real-world doctors under real-world circumstances, explained C.K. Wang, MD, senior medical director, COTA.


Real-world data offers a glimpse into what happens to patients treated by real-world doctors under real-world circumstances, explained C.K. Wang, MD, senior medical director, COTA.

Transcript

With limited patient populations involved in clinical trials, how can real-world data provide a more comprehensive picture of a drug’s efficacy?

There are many fundamental differences between clinical trial data and real-world data, or RWD. Clinical trial data essentially is the result of well-controlled scientific studies, and the patient that typically enrolls on a clinical trial is generally younger, more fit, and whiter than the general population. The real-world data, on the other hand, is essentially a glimpse into the information that currently exists in every provider’s office, and it constitutes patients from all ethnic backgrounds, socioeconomic status, and it gives us a very comprehensive view of what happens and essentially is a glimpse into what happens to patients treated by real-world doctors under real-world circumstances.

This insight that real-world data can give is very valuable or can be very valuable to life sciences companies in their attempts to help accelerate drug discovery and approval, as well as to monitor real-world treatment outcomes and treatment-related side effects. I think the best example of this is the most recent FDA approval, actually from yesterday, of a drug to treat a specific subtype of male breast cancer, which is a very rare cancer, and the study that led to this drug’s expanded approval essentially used real-world data in its study design. I think going forward, real-world data will be used more frequently to help life sciences companies to help accelerate their attempts to drug discovery and drug approval.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up